UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
the
month of March 2006
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
Kiryat
Weizmann Science Park
3
Hasapir Street, Building 3, PO Box 370
Rehovot
76100, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): o
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
XTL
Biopharmaceuticals to Present at the Brean Murray, Carret Small Cap
Institutional Investor Conference
NEW
YORK, Monday, January 30, 2006:
XTL
Biopharmaceuticals, Ltd. (Nasdaq: (LSE: XTL ; NASDAQ: XTLB ; TASE: XTL), a
biopharmaceutical company developing drugs against hepatitis, announced today
that Ron Bentsur, Chief Executive Officer, will present an overview of the
Company at The Brean Murray, Carret Small Cap Institutional Investor Conference
in New York City. Mr. Bentsur's presentation will take place on Wednesday,
February 1, 2006 at 11:30 a.m. Eastern Time at the Grand Hyatt New York Hotel.
A
live audio webcast of Mr. Bentsur's presentation will be available at
http://www.wsw.com/webcast/bmry2/xtl/.
An
archived version of the webcast will be available following the conclusion
of
the live presentation.
Contact:
Ron
Bentsur, Chief Executive Officer Tel:
+1-212-531-5971
About
XTL Biopharmaceuticals Ltd.
XTL
Biopharmaceuticals Ltd. ("XTLbio") is engaged in the research, development
and
commercialization of therapeutics for the treatment of infectious diseases;
with
a primary focus on hepatitis C. XTLbio's most advanced therapeutic in Hepatitis
C is XTL-6865 - a combination of two monoclonal antibodies against the hepatitis
C virus - presently in Phase 1 clinical trials in patients with chronic
hepatitis C. XTLbio's second Hepatitis C therapeutic is XTL-2125 - a small
molecule inhibitor of the hepatitis C virus polymerase - expected to enter
Phase
1 clinical trials in 1H2006. XTLbio hepatitis C pipeline also includes
several families of pre-clinical hepatitis C small molecule inhibitors. In
addition, XTL has out-licensed to Cubist Pharmaceuticals an antibody therapeutic
against hepatitis B, HepeX-B, which has recently completed a Phase 2b clinical
study in transplant patients. XTLbio is publicly traded on the London,
NASDAQ, and Tel-Aviv Stock Exchanges (LSE: XTL; NASDAQ: XTLB; TASE:
XTL).
XTL
Biopharmaceuticals to Present at the JPMorgan Small Cap Conference
NEW
YORK, February 13, 2006
- XTL
Biopharmaceuticals, Ltd. (LSE: XTL ; NASDAQ: XTLB ; TASE: XTL), a
biopharmaceutical company developing drugs against hepatitis, announced today
that Ron Bentsur, Chief Executive Officer, will present an overview of the
Company at The JPMorgan Small Cap Conference in Philadelphia. Mr. Bentsur's
presentation will take place on Thursday, February 16, 2006 at 9:30 a.m. Eastern
Time at the Four Seasons Hotel. A live audio webcast of Mr. Bentsur's
presentation will be available at
http://equityconferences.jpmorgan.com.
An
archived version of the webcast will be available following the conclusion
of
the live presentation.
Contact:
Ron
Bentsur, Chief Executive Officer Tel:
+1-212-531-5971
About
XTL Biopharmaceuticals Ltd.
XTL
Biopharmaceuticals Ltd. ("XTLbio") is engaged in the research, development
and
commercialization of therapeutics for the treatment of infectious diseases,
with
a focus on hepatitis C. XTLbio is developing XTL-2125 - a small molecule,
non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is
expected to enter Phase I clinical trial in 1H 2006. XTLbio is also developing
XTL-6865 - a combination of two monoclonal antibodies against the hepatitis
C
virus - presently in Phase 1 clinical trials in patients with chronic hepatitis
C. XTLbio’s hepatitis C pipeline also includes several families of pre-clinical
hepatitis C small molecule inhibitors. In addition, XTL has out-licensed
to Cubist Pharmaceuticals an antibody therapeutic against hepatitis B, HepeX-B,
which has recently completed a Phase 2b clinical study in transplant patients.
XTLbio is publicly traded on the London, NASDAQ, and Tel-Aviv Stock
Exchanges (LSE: XTL; NASDAQ: XTLB; TASE: XTL)
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
|
|
| |
XTL
BIOPHARMACEUTICALS LTD. |
|
|
|
| Date: March
6, 2006 |
By: |
/s/ Jonathan
Burgin |
| |
Jonathan
Burgin |
| |
Chief
Financial Officer
|